Stay updated on First-Line Tarlatamab Combo in ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.

Latest updates to the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page
- ChecktodayChange DetectedThe Publications section was updated to clarify that PubMed items are auto-filled and to specify the page revision numbers (v3.3.2 vs v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check7 days agoChange DetectedLocation entry changed from Tainan City, Taiwan, 70403 to Tainan, Taiwan, 70403; the government funding lapse notice banner was removed.SummaryDifference0.3%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe differences are minor UI and formatting adjustments to the Study Details page without changes to core study data such as eligibility criteria, primary outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check36 days agoChange DetectedMinor metadata update: the citation’s online-ahead-of-print note and date formatting were adjusted; core study information remains the same.SummaryDifference0.6%

- Check51 days agoChange DetectedCore content updated with a government funding notice and updated operating-status guidance; version updated from v3.1.0 to v3.2.0.SummaryDifference3%

- Check58 days agoChange DetectedUpgrade version from v3.0.2 to v3.1.0. No other content changes are specified.SummaryDifference0.1%

Stay in the know with updates to First-Line Tarlatamab Combo in ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.